Diabetic Retinopathy and Skin Tissue Advanced Glycation End Products Are Biomarkers of Cardiovascular Events in Type 2 Diabetic Patients
Planas, Alejandra (Vall d'Hebron Institut de Recerca (VHIR))
Simó-Servat, Olga (Vall d'Hebron Institut de Recerca (VHIR))
Hernández, Cristina (Vall d'Hebron Institut de Recerca (VHIR))
Ortiz Zúñiga, Ángel Michael (Vall d'Hebron Institut de Recerca (VHIR))
Marsal, Josep Ramon (Hospital Universitari Vall d'Hebron)
Herance Camacho, José R. (Hospital Universitari Vall d'Hebron)
Ferreira-Gonzalez, Ignacio (Hospital Universitari Vall d'Hebron)
Simó Canonge, Rafael (Vall d'Hebron Institut de Recerca (VHIR))

Data:	2021
Resum:	Risk of cardiovascular events is not homogeneous in subjects with type 2 diabetes; therefore, its early identification remains a challenge to be met. The aim of this study is to evaluate whether the presence of diabetic retinopathy and accumulation of advanced glycation end-products in subcutaneous tissue can help identify patients at high risk of cardiovascular events. For this purpose, we conducted a prospective study (mean follow-up: 4. 35 years) comprising 200 subjects with type 2 diabetes with no history of clinical cardiovascular disease and 60 non-diabetic controls matched by age and sex. The primary outcome was defined as the composite of myocardial infarction, coronary revascularization, stroke, lower limb amputation or cardiovascular death. The Cox proportional hazard multiple regression analysis was used to determine the independent predictors of cardiovascular events. The patients with type 2 diabetes had significantly more cardiovascular events than the non-diabetic subjects. Apart from the classic factors such as age, sex and coronary artery calcium score, we observed that the diabetic retinopathy and advanced glycation end-products in subcutaneous tissue were independent predictors of cardiovascular events. We conclude that the diabetic retinopathy and advanced glycation end-products in subcutaneous tissue could be useful biomarkers for selecting type 2 diabetic patients in whom the screening for cardiovascular disease should be prioritized, thereby creating more personalized and cost-effective medicine.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Cardiovascular disease ; Advanced glycation end-products ; Diabetic retinopathy ; Cardiovascular disease biomarkers ; Type 2 diabetes ; Diabetic complications
Publicat a:	Journal of personalized medicine, Vol. 11 (december 2021) , ISSN 2075-4426

DOI: 10.3390/jpm11121344
PMID: 34945815

10 p, 630.9 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats